

Kiel University Christian-Albrechts-Universität zu Kiel

Faculty of Medicine

Forschungsbezogene Verwendung klinischer Daten: Was wollen die Patienten?

Gesine Richter

Institute of Epidemiology – Christian-Albrechts-Universität zu Kiel, Germany gesine.richter@iem.uni-kiel.de



Broad Consent and no-consent policy: Studies assessing acceptance and motivation

| | Study 1 | Study 2 | | | |
|-------|---|--|--|--|--|
| Who? | Patients at the Comprehensive Center for Inflammation Medicine (CCIM), UKSH, Campus Kiel | | | | |
| When? | 2015/2016 | 03/2018 (shortly before GDPR came into force | | | |
| Aim | Understanding & acceptance of broad consent , motivation to give broad consent | Acceptance of broad consent , motivation, Acceptance of a no-consent policy , motivation | | | |
| How? | 760 delivered questionnaires, 550 completed questionnaires (73,4%) | 700 delivered questionnaires 503 completed questionnaires (72%) | | | |
| | Richter G, Krawczak M, Lieb W, Wolff L, Schreiber S, Buyx A, Genetics in Medicine 2018. | Richter G, Borzikowsky C, Lieb W, Schreiber S, Krawczak M, Buyx A, European Journal of Human Genetics 2019 | | | |



Broad Consent and no-consent policy: Studies assessing acceptance and motivation Motivation to give broad consent

| | | Study 1 | | Study 2 | |
|----------------------------------|--|-------------|---------------|-------------|--|
| Acceptance to give broad consent | | 80 | 5 ,9 % | 93% | |
| Motivatio | on to give broad consent | | | | |
| ale t | Support of research in general | 188 (77.1%) | 48 (20.5%) | 403 (86.1%) | |
| Altruism | Helping all future patients | 120 (49.2%) | 131 (56.0%) | 315 (67.3%) | |
| California. | Helping future patients with same disease | 157 (64.3%) | 89 (38.0%) | 328 (70.1%) | |
| Solidarity | Feeling connected with future patients | 55 (22.5%) | 32 (13.7%) | 189 (40.4%) | |
| Reciprocity | Returning own benefit from research | 118 (48.4%) | 92 (39.3%) | 339 (72.4%) | |
| Gratitude | Gratitude toward doctors | 115 (47.1%) | 126 (53.9%) | 214 (45.7%) | |
| Other | Other Hope for personal benefit, Acting as a role model, Worry about disadvantages if not consenting, Knowing of others who consented, <u>No specific reasons</u> | | | | |



Broad Consent and no-consent policy: Studies assessing acceptance and motivation Motivation not to give broad consent

| | Study 1 | Study 2 |
|--|---------|------------|
| Acceptance to give broad consent | 86,9% | 93% |
| Motivation not to give broad consent | | |
| Worries about data security | | 14 (40.0%) |
| Wanting to know type of research | | 13 (37.1%) |
| Wanting to know who does research | | 12 (34.3%) |
| Denial of research on other than own disease | | 5 (14.3%) |
| No personal benefit expected from consenting | | 4 (11.4%) |
| Insufficient personal benefit from research so far | | 3 (8.6%) |
| No specific reasons | | 7 (20.0%) |



No-consent policy: Study assessing acceptance and motivation Attitude towards no-consent policy

| | Study 2 |
|-------|----------------|
| 86,9% | 93% |
| | 76 % (n = 381) |
| | 24% (n=122) |
| | 86,9% |

Positive correlation between acceptance to give broad consent and non-consent policy

| Acceptance to give broad consent | 93% (n=468) | Acceptance of no-consent-policy | 79 % (n=371) |
|---|-------------|--|--------------|
| Refusal to give broad consent | 7% (n=35) | Refusal of no-consent-policy | 71% (n=25) |



Forschungsbezogene Verwendung klinischer Daten: was wollen die Patienten? 08/2019 | Gesine Richter No-consent policy: Study assessing acceptance and motivation Reasons for acceptance of no-consent policy

| | | Study 2 | | |
|---|-------|---------------|--|--|
| ttitude towards research without consent 7 | | 6 % (n = 381) | | |
| How would you find a regulation in which patients would no longer have to consent separately to the use of their data and biomaterials for scientific research purposes under the conditions mentioned? | | | | |
| regulation is good, because we all benefit from the results of the research and that will only work if we all participate | | 61% (n=233) | | |
| regulation is good , but a special commission should decide on the of data and biomaterials | use | 25% (n=95) | | |
| regulation is good, but it should apply only to certain areas of rese | earch | 23 % (n=89) | | |

No-consent policy: Study assessing acceptance and motivation Reasons for refusal of no-consent policy

| | Study 2 |
|------------------------------|-------------|
| Refusal of no-consent policy | 24% (n=122) |

How would you find a regulation in which patients would no longer have to consent separately to the use of their data and biomaterials for scientific research purposes under the conditions mentioned?

| regulation is not good , because I can no longer decide on the use of data and biomaterials | 73% (n=89) |
|---|------------|
| regulation is not good , because I do not see who controls the use of data and biomaterials | 59% (n=72) |
| regulation is not good, because I fear disadvantages for myself | 7 % (n=9) |



Conclusion and Discussion

- **1.** Willingness to give broad consent was very high in our study main motivations to give broad consent were altruism, reciprocity, and solidarity
- 2. High approval (n=381, 76%) of no-consent policy that allows research with clinical data without patient consent under certain conditions
- **3.** Moderately positive correlation between the willingness to give broad consent and the approval of a no-consent-policy
- **4.** Demand for transparent infrastructure to regulate access to data.
- 5. Offer the dissenting group a choice that allows preserving their autonomy and self-determination, e.g. by the introduction of opt-out mechanisms



Acknowledgements

Co-authors of the project

Michael Krawczak, MSc, PhD Christoph Borzikowsky, PhD Institute of Medical Informatics and Statistics, Kiel University, Germany

Wolfgang Lieb, MD, PhD Institute of Epidemiology, Kiel University

Stefan Schreiber, MD, PhD Inst. of Clinical Molecular Biology, Kiel University

Alena Buyx, MD, PhD

Institute of History and Ethics in Medicine, Technical University of Munich

Special thanks to the patients and the collegues of the Comprehensive Center for Inflammation Medicine (CCIM) at the University Hospital Schleswig-Holstein (UKSH), Kiel



Thank you very much for your attention.

